Standard versus low‐dose nab‐paclitaxel in previously treated patients with advanced non‐small cell lung cancer: A randomized phase <scp>II</scp> trial (<scp>JMTO LC14</scp>‐01)

Susumu Takeuchi(Nippon Medical School), Masaaki Kawahara(The Japan-Multinational Trial Organization), Seigo Minami(Osaka National Hospital), Akihiko Gemma(Nippon Medical School), Hiroshi Kuraishi(Nagano Red Cross Hospital), Satoshi Teramukai(Kyoto University Hospital), Kei Fujikawa(Kyoto Prefectural University of Medicine), Tomoiki Aiba(Sendai Kousei Hospital), Masahiro Seike(Nippon Medical School Hospital), Shinji Atagi(National Institute of Technology, Nara College), Shunichi Sugawara(Sendai Kousei Hospital), Rintaro Noro(Xanadu Quantum Technologies (Canada)), Kaoru Kubota(Nippon Medical School Hospital), Yuji Minegishi, Masaru Matsumoto(Ishikawa Prefectural Nursing University), Shinichiro Iida(Otemae Hospital), Takashi Hirose(SHOWA Medical University)
Cancer Medicine
February 21, 2023
10.1002/cam4.5652
Cited by 8

Related Papers

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.4k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Osimertinib with or without Chemotherapy in <i>EGFR</i> -Mutated Advanced NSCLC
|New England Journal of Medicine|2023|695